In 2025, Bristol-Myers Squibb completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Bristol-Myers Squibb has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 210,246a | 199,170a | 213,510a | |
Total Scope 2 | ||||
Market-Based | 64,264a | 67,508a | 112,593a | |
Location-Based | 120,791a | 119,679a | 117,052a | |
Total Scope 3 | 1,569,246a | 1,678,764a | 1,939,962a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.3624a | 4.1236a | 4.744a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb amounted to 331,037 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb increased by 3.82%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Bristol-Myers Squibb were 210,246 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Bristol-Myers Squibb's Scope 1 emissions have decreased by 3.64%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), Bristol-Myers Squibb's Scope 1 emissions increased by 5.56%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Bristol-Myers Squibb reported Scope 2 greenhouse gas (GHG) emissions of 64,264 tCO₂e using the market-based method and 120,791 tCO₂e using the location-based method.a
Compared to the previous year (2024), Bristol-Myers Squibb's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Bristol-Myers Squibb reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Bristol-Myers Squibb reported 1,569,246 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Bristol-Myers Squibb includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Bristol-Myers Squibb reported total Scope 3 emissions of 1,569,246 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 93.01% of these emissions originated from upstream activities such as purchased goods and capital goods, while 6.99% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Bristol-Myers Squibb's Scope 3 emissions have increased by 1,419.12%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2024), Bristol-Myers Squibb's Scope 3 emissions remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Bristol-Myers Squibb reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2025, the largest contributors to Bristol-Myers Squibb's Scope 3 emissions were:a
In 2025, Bristol-Myers Squibb reported Scope 1 greenhouse gas (GHG) emissions of 210,246 tCO₂e and total revenues of USD 48,195 millions. This translates into an emissions intensity of 4.36 tCO₂e per millions USD.a
In 2025, Bristol-Myers Squibb reported a Scope 1 emissions intensity of 4.36 tCO₂e per millions USD. Compared to the peer group median of 4.98, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Bristol-Myers Squibb ranked 11 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Bristol-Myers Squibb is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Bristol-Myers Squibb reported a total carbon footprint of 1,900,283 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 4.87% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Bristol-Myers Squibb's total carbon footprint was Scope 3 emissions, accounting for 82.58% of the company's total carbon footprint, followed by Scope 1 emissions at 11.06%.a